A Phase 2a Study of TPN-101 in Patients with Progressive Supranuclear Palsy
Enrolling By Invitation
41 years - 86 years
All
Phase
2
6 participants needed
1 Location
Brief description of study
The research study
is being conducted to assess the safety and tolerability of TPN-101 compared to
placebo for the treatment of PSP. The study requires the participant and a caregiver to be part of the study.
If you agree to
join the study, you will be asked to complete the following research
procedures:
· Physical
exams
· Blood
and Urine collection
· DNA
Testing
· Cerebrospinal
fluid (CSF) sampling
· Pregnancy
Test
· Electrocardiogram
(ECG)
· Questionnaires
· Blood
Sampling for Future Testing (optional)
Your participation
will last for approximately 58 weeks.
You may not
receive any benefit from being in this study. The most common risks of
participation are:
· Nausea,
headache, abdominal pain, and fatigue
· Allergic
reactions
The study will primarily recruit patients from within the Penn Medicine practices. In order to see if you qualify please contact us by email.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: progressive supranuclear palsy
-
Age: 41 years - 86 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 850052
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
